On February 10, 2021 PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer reported the fimaNAc focused presentation for the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021 (Press release, PCI Biotech, FEB 10, 2021, View Source [SID1234585153]). The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Today, Wednesday February 10 2021, at 13:10pm (CET) Dr. Anders Høgset, CSO, will present an overview of PCI Biotech’s proprietary platform technology, focusing on the delivery of RNA molecules, including the most recent data on the use of the fimaNAc delivery technology in the exciting field of RNA based therapies.
Per Walday, CEO of PCI Biotech, comments: Encouraging collaborative preclinical results have recently been achieved with the fimaNAc technology and we are very pleased to be able to share these data now. The rapid development progress of mRNA-based vaccines against Covid-19 has generated much attention to the potential of nucleic acid therapeutics generally, and mRNA particularly. The results with fimaNAc suggests that this technology provides an appealing intracellular delivery solution for certain applications within this class of therapeutics.
An online recording of the full presentation held by Dr Høgset will be made available on PCI Biotech’s website (www.pcibiotech.com) under "Scientific publications & presentations" after the event.